Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1635 in B-Cell Malignancies
NCT07583212Phase 1Recruiting
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Jun 2026
- Primary completion
- Oct 2028
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-1635 in B-cell malignancy, sponsored by Chengdu Suncadia Pharmaceuticals. Primary endpoints: Incidence and severity of adverse events at 2 years and Dose-limiting toxicity at 23 days. Started Jun 2026; status: recruiting.
02
Drugs
HRS-1635
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT07583212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07583212.